Tirzepatide (CAT: I018932) is an investigational medication being developed for the treatment of type 2 diabetes mellitus. It is a peptide-based dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide combines the actions of GIP and GLP-1 to stimulate insulin secretion, inhibit glucagon release, and regulate blood sugar levels. By targeting both receptors, tirzepatide has the potential to provide improved glycemic control compared to single-receptor agonists. Clinical trials have shown promising results in terms of glycemic control, body weight reduction, and cardiovascular outcomes.
| Catalog Number | I018932 |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Purity | 95% |
| Reference | [1]. Frias JP, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-2193. |
